FindTrial
Sign In

agenT-797

DRUG8 trials

Sponsors

MiNK Therapeutics, Memorial Sloan Kettering Cancer Center, ImmunityBio, Inc., Darren Sigal, MD, University of Wisconsin, Madison

Conditions

Acute Myeloid LeukemiaAcute Respiratory Distress Syndrome (ARDS)Advanced Unresectable Gastric AdenocarcinomaAllogenic Stem Cell TransplantationChronic Myeloid LeukemiaColorectal Cancer MetastaticCommunity-Acquired Pneumonia (CAP)Immunoparalysis

Phase 1

A Clinical Trial to Evaluate the Safety of agenT-797 in COVID-19 Participants With ARDS
CompletedNCT04582201
MiNK TherapeuticsRespiratory Distress Syndrome, Adult
Start: 2020-09-21End: 2023-04-23Updated: 2025-12-30
agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma
CompletedNCT04754100
MiNK TherapeuticsRelapsed/Refractory Multiple Myeloma
Start: 2021-03-29End: 2023-05-31Updated: 2023-06-06
A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors
CompletedNCT05108623
MiNK TherapeuticsTumor, Solid
Start: 2022-01-28End: 2024-01-02Updated: 2024-04-24
Allogeneic iNKT Cell Therapy (agenT-797) After SCT
Not yet recruitingNCT07758218
University of Wisconsin, MadisonAcute Myeloid Leukemia, Allogenic Stem Cell Transplantation, Chronic Myeloid Leukemia +3
Start: 2026-10-01End: 2029-10-01Target: 22Updated: 2026-08-11

Phase 2

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer
Active, not recruitingNCT06251973
Memorial Sloan Kettering Cancer CenterAdvanced Unresectable Gastric Adenocarcinoma, Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Cancer +10
Start: 2024-02-01End: 2027-08-01Updated: 2026-05-15
BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases
RecruitingNCT07550088
Darren Sigal, MDColorectal Cancer Metastatic
Start: 2026-06-10End: 2028-12-01Target: 17Updated: 2026-08-10
A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure
RecruitingNCT07615010
MiNK TherapeuticsPneumonia
Start: 2026-05-26End: 2027-08-01Target: 90Updated: 2026-06-26

Phase 3

Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia
WithdrawnNCT07492875
ImmunityBio, Inc.Acute Respiratory Distress Syndrome (ARDS), Community-Acquired Pneumonia (CAP), Immunoparalysis +2
Start: 2026-04-15End: 2029-12-31Updated: 2026-05-08

Related Papers

A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome
Nature Communications2024-02-0629 citations
735 Peripheral and tissue persistence of agenT-797, an allogeneic iNKT cell-based cell therapy for the treatment of cancer
Regular and Young Investigator Award Abstracts2023-10-313 citations
647 Phase I studies of AgenT-797, a novel allogeneic invariant natural killer T (iNKT) cell therapy, for the treatment of patients with solid tumors or multiple myeloma
Regular and Young Investigator Award Abstracts2022-11-013 citations
649 Phase 1/2 study of AgenT-797, an allogeneic invariant natural killer T (iNKT) cell therapy, in subjects with moderate to severe acute respiratory distress syndrome (ARDS) secondary to SARS-CoV-2 (COVID-19)
Regular and Young Investigator Award Abstracts2022-11-013 citations
400 Persistence and tissue distribution of agent-797 – a native allogeneic iNKT cell-therapy drug product
Regular and Young Investigator Award Abstracts2021-11-011 citations